



ADVANCED COURSE ON  
UNSOLVED QUESTIONS  
IN IMMUNO-ONCOLOGY



## ESMO Advanced Course on Unsolved questions in Immuno-Oncology 16-17<sup>th</sup> February 2018, Amsterdam, Netherlands

**Co-Chairs:** John B.A.G. Haanen, Netherlands  
Martin Reck, Germany

**Speakers:** Stéphane Champiat, France  
Keith Kerr, United Kingdom  
Aurélien Marabelle, France  
Erika Martinelli, Italy  
Matthias Preusser, Austria

### Learning Objectives

- The development of immuno-therapy in Medical Oncology has been practice changing for several frequent tumour types and established Immunotherapy as an additional class of therapeutics
- Patient selection based of immune biomarkers may be associated with efficacy (predictive factor) but still remains controversial and other biomarkers could help in patient selection
- The mechanism of action of Immune Check Point Inhibitors differs greatly from conventional cancer treatment and efficacy evaluation needs to be adapted
- The systemic manipulation of the Immune system has proven efficacy against cancer cells but may also be associated with alteration of normal tissues or organs, targeted by Immune Check Point Inhibitors and consequently auto-immune or auto-immune-like side effects have been reported

### Accreditation

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

### Acknowledgements

This event is supported by an unrestricted educational grant.



## **Friday 16th February**

### **09:00-09:40 Welcome and Introduction**

Welcome

John B.A.G. Haanen, NL

The present state-of-the-art of Immune Check-point Inhibitors in oncology

John B.A.G. Haanen, NL

### **09:40-10:40 Session 1 – Patient selection**

Is there a clear correlation between PD-L1 expression and outcome? The Medical Oncologist point of view

Martin Reck, DE

Strengths and weaknesses of PD-L1 testing: the pathologist point of view

Keith Kerr, UK

### **10:40-11:10 Coffee Break**

### **11:10-11:40 Session 1 – cont. Patient selection**

Immunogram, immunoprofiling, immunoscores and other biomarkers of potential use

John B.A.G. Haanen, NL

### **11:40-12:10 Session 2 – Immune-related toxicities**

ESMO Guidelines: management of toxicities from immune checkpoint inhibitors

John B.A.G. Haanen, NL

### **12:10-13:10 Lunch**

### **13:10-15:10 Session 3 – Special situations**

Patients with brain metastasis

Matthias Preusser, AT

Patients with liver metastasis or liver primary tumours

Erika Martinelli, IT

Patients with previous organ transplant

Stéphane Champiat, FR

The issue of fast progression

Stéphane Champiat, FR

### **15:10-15:40 Coffee break**

### **15:40-16:40 Session 4 – Treatment delivery: dosing and duration**

Are patients overdosed with the present recommendations?

Aurélien Marabelle, FR

Should treatment be prolonged indefinitely? Could a maintenance phase be used?

John B.A.G. Haanen

## **Saturday 17th February**

### **9:00-12:30 Workshops sessions**

Three parallel workshops sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotation basis)

15' Introduction based on clinical cases presented by speakers

35' Discussion

10' Break

### **Workshop 1 Patient selection based on selected biomarkers**

Martin Reck, DE

### **Workshop 2 Immune-related toxicity and duration of treatment**

Aurélien Marabelle, FR

John B.A.G Haanen, NL

### **11:00-11:30 Coffee Break**

### **Workshop 3 Special situations**

Stéphane Champiat, FR

Matthias Preusser, AT

Erika Martinelli, IT

### **12:30-13:15 Feedback on the workshop from each group**

### **13:15-13:30 Synthesis and wrap-up**

John B.A.G. Haanen

### **13:30-14:30 Lunch**